Finding the optimal regimen for short-term daily recombinant human erythropoietin treatment for blood-saving purpose in patients undergoing unilateral primary total hip arthroplasty: a double-blinded randomized placebo-controlled trial

Peer Review reports

Original Submission
29 Jul 2021	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
25 Oct 2021	Reviewed	Reviewer Report
3 Dec 2021	Reviewed	Reviewer Report - Bhaveen H. Kapadia
17 Dec 2021	Author responded	Author comments - Zongke Zhou
Resubmission - Version 3
17 Dec 2021	Submitted	Manuscript version 3
29 Dec 2021	Author responded	Author comments - Zongke Zhou
Resubmission - Version 4
29 Dec 2021	Submitted	Manuscript version 4
18 Jan 2022	Reviewed	Reviewer Report - Bhaveen H. Kapadia
20 Jan 2022	Reviewed	Reviewer Report
17 Feb 2022	Author responded	Author comments - Zongke Zhou
Resubmission - Version 5
17 Feb 2022	Submitted	Manuscript version 5
Publishing
4 Mar 2022	Editorially accepted
12 Mar 2022	Article published	10.1186/s12891-022-05184-1

Back to article page